Transdermal Patches

FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia

Approvals, Atypical Antipsychotics, Blood Pressure, Boxed Warning, Clinical Data, FDA, FDA/Regulatory, Schizophrenia, Shares, Transdermal Patches

Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.

FDA approves Amneal’s generic dementia patch

Alzheimer’s Disease, Approvals, Biologics, Biosimilars, Department of Health and Human Services (HHS), Drug Competition Action Plan, FDA, FDA/Regulatory, Generics, J.P. Morgan Healthcare Conference, Market Value, Parkinson’s disease, Patches, Patent Litigation, Product Pipelines, Transdermal Patches

The U.S. FDA approved Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.

Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

Nausea and Vomiting, Pregnancies, Technology, Transdermal Patches

Aequus Pharmaceuticals Inc. announced an expansion of its relationship with Corium International Inc. to include the company’s long-acting transdermal patch AQS1303 for the treatment of nausea and vomiting in pregnancy.